Five Prime Therapeutics Inc. said a combination of its therapy cabiralizumab with Bristol-Myers Squibb Co.'s Opdivo failed to improve survival rate in patients with pancreatic cancer.
The randomized clinical trial evaluated the combination therapy in 160 patients with advanced pancreatic cancer that progressed during or after one line of chemotherapy. "Pancreatic cancer is a difficult disease to treat, and unfortunately the combination of cabiralizumab and Opdivo with and without chemotherapy did not show any meaningful benefit over standard of care chemotherapy in this randomized, controlled phase 2 trial," said Helen Collins, executive vice president and chief medical officer of Five Prime.
The primary goal of the study was to increase the survival in patients without the disease getting worse to up to 12 months.
Bristol-Myers does not have near term plans to sponsor additional development of cabiralizumab, Five Prime said. However, Bristol-Myers will continue to evaluate the drug in ongoing studies and may assess development opportunities in the future.